Damora Therapeutics, Inc.
DMRA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001800315
In the last 90 days, Damora Therapeutics, Inc. insiders filed 1 open-market purchase and 1 sale; 104 institutions reported holding it in 13F filings for Q2 2026, worth $1.67B in total; Viking Global Investors is the only superinvestor holding it.
13F holders, Q4 2022
Institutional positions in Damora Therapeutics, Inc. as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 22
- −4 vs. Q3 2022
- Shares held
- 8.88M
- −283.3K (−3.1%) vs. Q3 2022
- Total value
- $10.2M
- −$7.11M (−41.0%) vs. Q3 2022
- New holders
- 1
- 5 more added
- Sold out
- 5
- 6 more reduced
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting DMRA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 104 | $1.67B |
| Q1 2026 | 65 | $1.45B |
| Q4 2025 | 18 | $65.5M |
| Q3 2025 | 12 | $633.3K |
| Q2 2025 | 9 | $451.5K |
| Q1 2025 | 11 | $442.4K |
| Q4 2024 | 10 | $660.7K |
| Q3 2024 | 10 | $1.56M |
| Q2 2024 | 22 | $1.91M |
| Q1 2024 | 26 | $3.09M |
| Q4 2023 | 22 | $2.77M |
| Q3 2023 | 22 | $3.92M |
| Q2 2023 | 27 | $25.7M |
| Q1 2023 | 26 | $17.8M |
| Q4 2022 | 22 | $10.2M |
| Q3 2022 | 26 | $17.3M |
| Q2 2022 | 23 | $15.7M |
| Q1 2022 | 25 | $21.0M |
| Q4 2021 | 26 | $30.5M |
| Q3 2021 | 25 | $37.2M |
| Q2 2021 | 27 | $57.4M |
| Q1 2021 | 19 | $82.9M |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding Damora Therapeutics, Inc.; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Arcus Capital Partners, LLC | 484 | $557 | 0.00% | +484 | New |
| JPMorgan Chase & Co | 854 | $1.00K | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 2,497 | $2.87K | 0.00% | −497−16.6% | Reduced |
| Tower Research Capital LLC (TRC) | 7,650 | $9.00K | 0.00% | +4,635+153.7% | Added |
| Commonwealth Equity Services, LLC | 10,179 | $11.0K | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 16,661 | $19.2K | 0.00% | 00.0% | Unchanged |
| Two Sigma Investments, LP | 17,431 | $20.0K | 0.00% | −29,113−62.5% | Reduced |
| Northern Trust Corp | 20,551 | $23.6K | 0.00% | 00.0% | Unchanged |
| Susquehanna International Group, LLP | 37,721 | $43.4K | 0.00% | −15,001−28.5% | Reduced |
| Vanguard Group Inc | 39,575 | $45.5K | 0.00% | +5,356+15.7% | Added |
| State Street Corp | 44,906 | $51.6K | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 49,910 | $57.4K | 0.00% | +3,072+6.6% | Added |
| Two Sigma Advisers, LP | 62,600 | $72.0K | 0.00% | −29,400−32.0% | Reduced |
| Federated Hermes, Inc. | 100,000 | $115.0K | 0.00% | +40,000+66.7% | Added |
| Geode Capital Management, LLC | 108,950 | $125.0K | 0.00% | +2,814+2.7% | Added |
| Renaissance Technologies LLC | 154,000 | $177.0K | 0.00% | −25,300−14.1% | Reduced |
| Bridgeway Capital Management, LLC | 173,100 | $199.1K | 0.01% | 00.0% | Unchanged |
| Laurion Capital Management LP | 190,652 | $219.3K | 0.01% | 00.0% | Unchanged |
| MAI Capital Management | 233,283 | $268.3K | 0.00% | −105,632−31.2% | Reduced |
| Cormorant Asset Management, LP | 1,020,238 | $1.17M | 0.08% | 00.0% | Unchanged |
| Novo Holdings A/S | 2,497,791 | $2.87M | 0.18% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 4,090,937 | $4.70M | 0.09% | 00.0% | Unchanged |
| Marquette Asset Management, LLC | 0 | $0 | 0.00% | −60,244−100.0% | Sold out |
| FNY Investment Advisers, LLC | 0 | $0 | 0.00% | −42,000−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −18,795−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −9,608−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −4,097−100.0% | Sold out |